Approved for public release; distribution unlimited 13. ABSTRACT (Maximum 200 We are studying how the signaling network composed of the Epidermal Growth Factor (EGF) family of peptide hormones and the ErbB family of receptor tyrosine kinases is differentially activated and coupled to physiologic responses. Because deregulation of this signaling network plays a significant role in the genesis or progression of several different human metastatic diseases, an understanding of the basic "wiring" of this network is required to elucidate the mechanisms of these diseases. We have generated a panel of cell lines based on the Interleukin-3 (IL3) -dependent Ba/F3 mouse hematopoietic cell line that ectopically express the four erbB family receptors. We have then identified the patterns of ErbB family receptor phosphorylation and IL3-independent responses stimulated by different EGF family hormones. We will present data supporting several concepts that have emerged from these studies:
(1) Differential Activation by EGF Family Hormones. EGF family hormones can be assigned to three distinct functional groups based on their stimulation of ErbB family receptor phosphorylation.
(2) Differential Coupling by ErbB Family Receptors. ErbB family receptors and combinations of receptors differentially couple to IL3-independent responses in Ba/F3 cells. Furthermore, ErbB family receptors directly activated by ligand binding behave differently from receptors activated in trans through receptor heterodimerization. Where copyrighted material is quoted, permission has been obtained to use such material.
Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
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In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985) .
For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
'V1%In the conduct of research utilizing recombinant DNA, the investigator (s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.
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In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. [Boring, et al., 1993] . One model is that breast cancer results from disruptions in the normal hormonal regulation of mammary gland epithelial cell proliferation and differentiation. We have undertaken experiments to characterize the signaling network composed of the epidermal growth factor (EGF) family of peptide hormones and the ErbB family of receptor protein tyrosine kinases. We also have begun experiments that assess the effects of this network on the proliferation, differentiation, and malignant growth transformation of mammary epithelial cells.
Therefore, these experiments are beginning to shed light on the role that these proteins play in breast carcinogenesis.
B. The EGF family/erbB receptor family signaling network
Deregulated signaling by the four receptor tyrosine kinases encoded by the Groenen, et al., 1994; Chang, et al., 1997; Carraway, et al., 1997] . While a single ErbB family receptor can in some cases bind more than one ligand (e.g. EGFR) , a single EGF family hormone can in some cases bind to multiple ErbB family receptors (e.g. BTC, EPR) Riese, et al., submitted] .
Furthermore, while an ErbB family receptor expressed by itself may not be stimulated by a given EGF family hormone, this receptor can be activated when coexpressed with another ErbB family receptor that can bind the hormone [Reviewed in Earp, et al., 1995] . For example, EGF does not bind or activate ErbB2 expressed on its own, but activates ErbB2 when coexpressed with the EGFR [Akiyama, et al., 1988; King, et al., 1988; Stern and Kamps, 1988; Connelly and Stern, 1990] . This "transmodulation" activation of ErbB2 by EGFR apparently occurs through the formation of EGF-driven receptor heterodimers and receptor cross-phosphorylation [Goldman, et al., 1990; Wada, et al., 1990; Qian, et al., 1992; Spivak-Kroizman, et al., 1992] .
The physiological responses to agonists for ErbB family receptors depends on their ability to coordinately activate multiple receptors that are differentially expressed and have different signaling capabilities. Although NRGs were initially purified by their ability to induce ErbB2 tyrosine phosphorylation, and were thought to be ligands for ErbB2, NRG does not bind ErbB2 and/or induce ErbB2 tyrosine phosphorylation in a variety of cell types or in solution [Culouscou, et al., 1993; Peles, et al., 1993; Plowman, et al., 1993b; Sliwkowski, et al., 1994; Tzahar, et al., 1994] .
Instead, NRG binds ErbB3 [Carraway, et al., 1994; Kita, et al., 1994; Sliwkowski, et al., 1994; Tzahar, et al., 1994] and ErbB4 [Plowman, et al., 1993a; Plowman, et al., 1993b; Culouscou, et al., 1993] . Co-expression of ErbB3 or ErbB4 with ErbB2 permits NRGinduced tyrosine phosphorylation of ErbB2, presumably through the formation of Page 8
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II. Materials and Methods

A. EGF Family Hormones
The production and/or synthesis of recombinant AR, NRGP3, and BTC have been described Riese, et al., 1996a; Riese, et al., 1996b] . 
B. Cell lines and cell culture.
The Ba/F3 mouse pro-B-lymphocyte cell line [Palacios and Steinmetz, 1985] and its derivatives were grown in RPMI (Gibco/BRL) supplemented with 10% fetal calf serum (Sigma) and Interleukin-3 (IL-3) supplied as 10% conditioned medium from the WEHI-3B mouse myelomonocytic leukemia cell line [Daley and Baltimore, 1988] . Ba/F3 derivatives transformed with constructs expressing ErbB family receptors were grown in medium supplemented with 200ug/ml G418 (Gibco/BRL).
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C. Plasmid constructions and generation of recombinant Ba/F3 derivatives.
The construction of recombinant retroviral vectors expressing the four ErbB family receptor cDNAs have been described previously . The generation and characterization of Ba/F3 derivatives expressing the four ErbB family receptors, singly and in every pairwise combination, have also been described previously .
D. Stimulation and analysis of erbB family receptor tyrosine phosphorylation.
The stimulation and analysis of ErbB family receptor tyrosine phosphorylation have been described earlier .
E. Stimulation and analysis of IL-3 independent responses.
The stimulation and analysis of IL-3 independent responses have been described earlier . We have subcloned the four different erbB family receptor cDNAs into the pLXSN recombinant retrovirus-based expression vector . We have also subcloned the neuregulin-(x cDNA into this same vector [Riese and Stern, unpublished data]. While we have packaged these constructs into recombinant retroviral stocks, these stocks were not used to generate the Ba/F3 derivatives described elsewhere in this report.
B. Develop cultured cell systems for expression and purification of recombinant neuregulin.
We have introduced a neuregulin-co (NRGo) expression vector into mouse C127 fibroblasts, generating cell lines that stably express and secrete NRGc'. We have also engineered recombinant baculovirus stocks containing a NRGoL cDNA.
However, we have not conclusively determined that infection of insect cells with these stocks results in the production of biologically active NRG(X. Dr. Frank Jones, a postdoctoral fellow in the Stern Laboratory, is continuing these efforts to produce biologically active recombinant NRG.
To bypass these difficulties in producing recombinant NRG, we established a collaboration with Drs. James D. Moyer, Brad C. Guarino, and Glenn C. Andrews, Pfizer Central Research, Groton, CT. They have supplied us with NRGI as a refolded, biologically active, chemically-synthesized 65-mer peptide corresponding to amino acids 177 to 241 of the NRG p31 isoform . We also established a collaboration with Drs. Sharon Buckley and Gregory D. We have purchased recombinant transforming growth factor alpha (TGFo•) and EGF from Collaborative Biomedical, and recombinant AR, NRGox, and BTC from R&D Systems.
C. Determine what erbB receptors are neuregulin effectors in Ba/F3 cells
As described previously, neuregulin-P (NRGI) stimulates ErbB4 tyrosine phosphorylation as well as ErbB3 tyrosine phosphorylation, but activates ErbB3 only when ErbB3 is coexpressed with another ErbB family receptor. Furthermore, NRGP stimulates EGFR and ErbB2 tyrosine phosphorylation when these receptors are coexpressed with either ErbB3 or ErbB4 (Figure 1 ).
D. Determine if neuregulin acts as an adhesion molecule or receptor for erbB proteins.
These experiments are being performed by Jonathan McMenamin-Balano, a predoctoral student in the Stern Laboratory. Preliminary evidence suggests that the membrane-bound, immature form of neuregulin acts as a receptor for ErbB3 or ErbB4 and that the cytoplasmic domain of neuregulin is coupled to cellular signaling pathways. As summarized in Figure 1 , EGF, AR, TGFcx, HB-EGF, and EPR stimulate EGFR tyrosine phosphorylation, as well as the phosphorylation of any other ErbB family receptor when it is coexpressed with the EGFR Riese, et al., submitted] . Surprisingly, BTC and EPR stimulate both EGFR and ErbB4 tyrosine phosphorylation. Furthermore, BTC stimulates both ErbB2 and ErbB3 tyrosine phosphorylation when these receptors are coexpressed with the EGFR. In contrast, BTC stimulates ErbB2 but not ErbB3 tyrosine phosphorylation when these receptors are coexpressed with ErbB4 [Riese, et al., 1996] . Therefore, NRG-j, EGF, and BTC all stimulate distinct patterns of ErbB family receptor tyrosine phosphorylation, which may in part account for their differential biological activities. [Li, et al., 1990] . Similarly, EGF stimulation of Ba/F3 cells expressing exogenous EGFR results in EGFR tyrosine phosphorylation and increased cellular DNA synthesis [Collins, et al., 1988; Shibuya, et al., 1990] , while stimulation of Ba/F3 derivatives expressing exogenous platelet derived growth factor (PDGF) receptor with PDGF results in receptor tyrosine phosphorylation and IL-3-independent proliferation [Satoh, et al., 1993] .
G. Determine if hormone-induced erbB receptor signaling confers IL-3 independent growth to
In the absence of ligand, all of the Ba/F3 derivatives remained dependent on IL-3 for survival, even those lines that display substantial basal receptor tyrosine phosphorylation . Activation of either EGFR or ErbB2 in the single recombinant cell lines was associated with IL-3 independent survival but not proliferation, while activation of ErbB3 or ErbB4 in the single recombinants had no biological effect Riese, et al., 1996] . Therefore, ligand stimulation of ErbB phosphorylation was necessary, but not sufficient, for an IL-3 independent response (Table 1) .
We also assessed ligand activity in the double recombinant Ba/F3 cell lines.
As expected from the responses of the single recombinant cell lines, receptor activation in cells expressing EGFR or ErbB2 conferred, with one notable exception, a minimal response of IL-3 independent survival. For example, in EGFR + ErbB2 (1+2), EGFR + ErbB4 (1+4), ErbB2 + ErbB3 (2+3), and ErbB2 + ErbB4 (2+4) cell lines, receptor activation stimulated a minimum of IL-3-independent survival, while in
ErbB-3 + ErbB4 (3+4) cells none of the ligands stimulated an IL-3 independent response Riese, et al., 1996a; Riese, et al., 1996b] . The exception is the response of 1+3 cells to ligand stimulation. As predicted, BTC and EGF stimulated the IL-3 independent survival of 1+3 cells; however, NRG-13 failed to stimulate an IL-3 independent response Riese, et al., 1996a] .
In some of the double recombinant cell lines ligand stimulation of coupling of multiple receptors to signaling pathways acted in a non-additive manner to stimulate an IL-3 independent response (Table 1) . In 1+2 cells BTC and EGF stimulated IL-3 independent proliferation, while in 1+4 cells EGF, BTC and NRG-P stimulated IL-3 independent proliferation Riese, et al., 1996a; . Therefore, while activation of either EGFR alone or ErbB2 alone stimulated IL-3 independent survival, activation of EGFR along with either ErbB2 or ErbB4 conferred IL-3 independent proliferation (Table 1) .
H. Identify cellular signaling proteins differentially coupled to each erbB family receptor.
We have previously established the four ErbB family receptor couple to different physiologic responses in Ba/F3 cells (Table 1 ). This suggests that each receptor is coupled to a distinct set of cellular signaling proteins. We have 
I. Determine if neuregulin-induced ErbB receptor signaling is capable of transforming the growth or altering the differentiative capacity of MCF-IOA cells.
We are currently establishing experimental conditions for this experiment.
See the section below for additional information about the effects of ErbB family receptor signaling on MCF-10A cells.
J. Characterize the responses of the MCF-1OA cell line to ErbB4 signaling.
There is mounting evidence that while activation of either EGFR or neu stimulates mammary cell proliferation and promotes tumorigenesis, increased ErbB4 signaling may inhibit proliferation or tumorigenesis by stimulating differentiation. Ectopic treatment of breast tumor cell lines with NRG inhibits their growth and stimulates milk protein synthesis [Peles, et al., 1992; Wen, et al., 1992] .
and NRG promotes the differentiation of breast cells in vivo [Krane and Leder, 1996; Jones, et al., 1996] . Furthermore, agonistic anti-ErbB4 antibodies stimulate the differentiation and inhibit the proliferation of human breast tumor cell lines [Chen, et al., 1996] . Moreover, ErbB4 overexpression in human mammary tumor samples correlates with markers for a more favorable prognosis, suggesting that ErbB4 signaling may inhibit tumorigenicity [Bacus, et al., 1996] .
We wished to examine the effects of increased ErbB4 signaling on the proliferation of MCF-10A cells. However, in these cells ErbB4 tyrosine Page 18
July 22, 1997 Grant #: DAMD17-94-J- 4036 David J. Riese II and David F. Stern "Heregulin-induced growth factor receptor signaling and breast carcinogenesis" phosphorylation is not stimulated by either NRG [Beerli, et al., 1995] or BTC (data not shown). Therefore, we tried to establish MCF-10A derivatives that ectopically overexpress ErbB4 through infection with a recombinant retrovirus containing the neomycin resistance gene (neoR) and the human ErbB4 cDNA (see section II.C.).
We noted that this retrovirus stock had an unusally low titer in MCF-10A cells and that the rare transformants that arose from infections with the ErbB4 retrovirus did not express higher levels of ErbB4 than the parental MCF-1OA cells (data not shown). A more careful analysis demonstrates that the low titer of the ErbB4 retrovirus stock is specific for ErbB4 ( Table 2 ), suggesting that ErbB4 is a growth suppressor in breast cells through coupling to cellular differentiation. Future experiments will examine the activity of ErbB4 mutants lacking cytoplasmic tyrosine residues that serve as sites for autophosphorylation and docking to receptor effector proteins. These experiments will identify signaling effectors required for the growth inhibitory effect of ErbB4 signaling in MCF-10A cells. In mammary cells, NRGs induce ErbB2 tyrosine phosphorylation, can be crosslinked to ErbB2, and binding is increased by ErbB2 overexpression [Peles, et al., 1993] . This suggests that ErbB2 is a receptor for NRG. However, NRG fails to induce ErbB2 tyrosine phosphorylation and/or bind ErbB2 when ErbB2-is expressed in fibroblasts, ovarian cells [Peles, et al., 1993] , CHO cells [Culouscou, et al., 1993; Plowman, et al, 1993b] , T-lymphoid cells [Plowman, et al., 1993b] , or COS-7 cells [Sliwokowski, et al., 1994] , and NRG does not bind to solubilized ErbB2 extracellular domains [Tzahar, et al., 1994] . Moreover, NRG binds ErbB3 [Carraway, et al., 1994; Kita, et al., 1994; Sliwkowski, et al., 1994; Tzahar, et al., 1994] or ErbB4 [Culouscou, et al., 1993; Plowman, et al., 1993a; Plowman et al., 1993b; Tzahar, et al., 1994] , and co-expression Page 20
July 22, 1997 Grant #: DAMD17-94-J- 4036 David J. Riese II and David F. Stern "Heregulin-induced growth factor receptor signaling and breast carcinogenesis" of ErbB3 or ErbB4 with ErbB2 confers NRG responsiveness upon ErbB2, probably through the formation of ErbB2/ErbB3 or ErbB2/ErbB4 heterodimers [Carraway, et al., 1994; Kita, et al., 1994; Plowman et al., 1993b; Sliwkowski, et al., 1994] . This has led to the general working hypothesis that activation of ErbB2 by NRG requires the presence of ErbB3 or ErbB4.
The present data are compatible with this conclusion, and extend the model to include NRG regulation of the EGFR. The EGFR and ErbB3 alone fail to respond to NRG for two different reasons. The EGFR does not bind NRG [Holmes, et al., 1992] , whereas ErbB3 binds, but is impaired for kinase activity [Guy, et al., 1994] . The stimulation of tyrosine phosphorylation of ErbB2 by NRG might suggest direct activation of ErbB2 by NRG, but in view of previously published work, is more likely to reflect interaction with endogenous ErbB3. However, ErbB4 is able to bind and respond to NRG directly. NRG induces extensive cross-talk among receptors expressed in binary combinations. Either ErbB3 or ErbB4, both of which bind NRG, enable regulation of the EGFR by NRG. This is the first evidence that NRG can regulate EGFR signaling.
As predicted from earlier work, NRG stimulates tyrosine phosphorylation of both receptors in the 2+3, 2+4, and 3+4 cell lines. Coexpression of EGFR, ErbB2, or ErbB4 with ErbB3 permits NRG induction of ErbB3 tyrosine phosphorylation. Although earlier work showed that expression of neu enhances tyrosine phosphorylation and NRG regulation of ErbB3 [Carraway, et al., 1994] , that work was done in COS-7 cells, which express significant basal amounts of ErbB2 and EGFR. Thus the present work [Pinkas-Kramarski, et al., 1996; Tzahar, et al., 1996; Graus-Porta, et al., 1997] . Finally, intrinsic differences between the exogenous human and endogenous mouse proteins may result in the differing capacities to undergo NRG-induced heterotypic receptor interactions.
While NRG can stimulate the tyrosine phosphorylation of each receptor under the appropriate conditions, the diversity of biological responses to NRG indicates that there must be additional mechanisms by which biological responses to NRG are specified. The patterns of NRG-induced stimulation of ErbB receptor tyrosine phosphorylation and IL-3 independent survival or proliferation demonstrates that there are several hierarchical levels at which biological responses to NRG are apparently specified. David J. Riese II and David F. Stern "Heregulin-induced growth factor receptor signaling and breast carcinogenesis" enables the IL-3 independent survival of cell lines expressing ErbB2, probably through NRG-induced activation of ErbB2 via ErbB3. However, NRG does not enable the IL-3 independent survival of EGFR + ErbB-3 cells, or of ErbB4 cells, even though NRG stimulates receptor tyrosine phosphorylation in these lines. This demonstrates that ErbB2 has signaling properties distinct from those of the EGFR, ErbB3, or ErbB4, and is consistent with earlier work showing that different ErbB family receptors can activate different signaling pathways and responses [DiFiore, et al, 1990; Fedi, et al., 1994; Kim, et al., 1994; Prigent and Gullick, et al., 1994; Soltoff, et al., 1994; Carraway, et al., 1995] . Neither NRG nor EGF induces IL-3-independent proliferation of cells that individually express ErbB4 or EGFR Riese, et al., 1996] . Yet, NRG stimulates IL-3-independent proliferation in the EGFR + ErbB-4 cell line. One simple explanation would be that IL-3-independent proliferation requires activation of two independent pathways, one of which is activated by the EGFR, and one by ErbB-4. An interesting alternative would be that the sites of EGFR and ErbB4 phosphorylation differ in ligand-induced EGFR/ErbB4 heterodimers than in ligand-induced receptor homodimers owing to substrate specificity of the receptor catalytic domains and steric considerations in the crossphosphorylation reaction. This would permit recruitment of unique signaling proteins to the heterodimer, resulting in unique biological responses. A model whereby a receptor is phosphorylated on different tyrosine residues by direct agonist binding compared to transmodulation is supported by the observation that while EGF stimulates IL3 independence in EGFR + ErbB3 cells, NRG does not Riese, et al., 1996a] . Furthermore, EGF and NRG stimulate different biochemical and physiologic responses in fibroblasts engineered to express EGFR and ErbB3, suggesting that EGFR activated directly and in trans couple to different signaling pathways and biological responses [Cohen, et al., 1996] . Thus, the diversity that BTC is a ligand for the EGFR [Watanabe, et al., 1994] . However, the effect of BTC on EGFR tyrosine phosphorylation and signaling and the possibility that BTC might activate other erbB family receptors were not assessed. Here we show that in Ba/F3 cells expressing only a single ectopic erbB family receptor, BTC stimulates the tyrosine phosphorylation of both the EGFR and, surprisingly, ErbB4 (Figure 1 ). This is consistent with the observation that radiolabeled BTC binds specifically to EGFR and ErbB4, but not to ErbB2 (Plowman, et al., in preparation) . Control experiments performed in parallel demonstrated that radiolabeled amphiregulin and EGF bound only to EGFR and radiolabeled NRG-P3 bound only to ErbB4, as previously reported.
Thus, BTC exhibits activities that are distinct from those displayed by EGF, which activates the EGFR alone, and NRG-f, which activates ErbB3 and ErbB4 (Figure 1) .
Analogous experiments have demonstrated that HB-EGF and EPR also activate both EGFR and ErbB4 [Elenius, et al., 1997; Riese, et al., submitted] (Figure 1 ).
Furthermore, in this first comprehensive analysis of ErbB family transmodulation for both BTC and EGF, we find that EGF can transmodulate ErbB4 in the EGFR + ErbB4 cell line. We also demonstrate that BTC stimulates a pattern of receptor Previous work demonstrated that different ErbB family receptors or combinations of receptors couple to distinct cellular signaling pathways. For example, EGFR activation stimulates the tyrosine phosphorylation of four proteins that are not highly phosphorylated following ErbB2 activation [Fazioli, et al., 1992] .
Furthermore, activated ErbB-stimulated higher levels of phosphatidylinositol 3-kinase than EGFR did [Fedi, et al., 1994; Soltoff, et al., 1994; Carraway, et al., 1995] , and it has been suggested that EGFR and ErbB2 bind the adapter protein GRB2, but ErbB3 does not [Prigent and Gullick, 1994 ; but also see Kim, et al., 1994; Fedi, et al., 1994] . The different coupling capacities of the erbB family receptors can be correlated Page 25
July 22,1997 Grant #: DAMD17-94-J- 4036 David J. Riese II and David F. Stern "Heregulin-induced growth factor receptor signaling and breast carcinogenesis" to specific biological responses. Activation of the EGFR stimulates the IL-3 independent proliferation of 32D myeloid cells, while wild-type and mutationallyactivated ErbB2 alleles do not [DiFiore, et al., 1990] . In Ba/F3 cells, activation of EGFR or ErbB2, but not ErbB4, stimulates IL-3 independent survival. Moreover, activation of EGFR and ErbB4 together stimulates IL-3 independent proliferation Riese, et al., 1996a] .
We found that BTC stimulates IL-3 independent survival or proliferation in Neu + ErbB-4 cells and in every cell line that expresses EGFR. In contrast, EGF stimulated IL-3 independence only in those cell lines that express EGFR while NRG-P stimulated IL-3 independence only in the EGFR + ErbB-4 cell line and in those cell lines that express ErbB2 Riese, et al., 1996a] . Therefore, with a single exception, the minimal requirement for IL-3 independence is activation of either EGFR or ErbB2. The exception is that BTC and EGF, but not NRG-P, stimulated IL-3 independent survival in the EGFR + ErbB3 cell line (Table 1 ). This lack of response to NRG-P may merely reflect the lower level of EGFR phosphorylation stimulated by NRG-1 in this cell line . On the other hand, the absence of biological response may reflect the different mechanism by which the EGFR is activated. As we have discussed earlier, the mechanism of receptor activation may partially define the sites of receptor autophosphorylation and coupling to downstream signaling proteins and physiologic responses [Cohen, et al., 1996; Graus-Porta, et al., 1997] . We demonstrated previously that coupling of these multiple receptor species to cellular signaling pathways acts in a non-additive manner in specifying biological responses [Riese, et al., 1996] . Accordingly, while activation of EGFR or ErbB2 by themselves stimulated IL-3 independent survival, activation of EGFR and either ErbB2 or ErbB4 together stimulated IL-3 independent proliferation (Table 1) Johnson and Williams, 1994; Barbacid, 1994] .
Another regulatory mechanism common to the EGF/ErbB and FGF signaling networks is that both use heparan sulfate proteoglycans (HSPGs) to modulate receptor-ligand interactions. FGFs bind with low affinity in a multivalent manner to HSPGs, causing ligand oligomerization [Reviewed in Lemmon and Schlessinger, 1994] and increasing their binding affinity for FGFRs [Reviewed in Eckenstein, 1994] .
Because the FGF/FGFR complex exists in a 1:1 stoichiometry [Spivak-Kroizman, et al., 1994 ], yet FGFs are monomeric, it has been proposed that HSPG binding David J. Riese II and David F. Stern "Heregulin-induced growth factor receptor signaling and breast carcinogenesis" 1994; Cook, et al., 1995a; Cook, et al., 1995b] . However, many of the mechanistic details of regulation by HSPGs have yet to be elucidated.
While the neurotrophin and FGF networks have regulatory mechanisms that are also features of the EGF/erbB network, there are also features of the neurotrophin and FGF networks that are not part of the EGF/ErbB network.
Alternative splicing produces truncated FGFR and Trk isoforms lacking the cytoplasmic tyrosine kinase domain and sites for tyrosine phosphorylation [Reviewed in Johnson and Williams, 1994; Barbacid, 1994 . Therefore, a regulatory mechanism not observed in the EGF/ErbB network results in dominant negative receptors, which are not a characteristic of the EGF/ErbB network. Another feature that is characteristic of the neurotrophin network and not seen in the EGF/erbB network is regulation by a low-affinity co-receptor. p75, the low-affinity neurotrophin receptor, has no tyrosine kinase domain [Reviewed in Chao, 1994 ] and p 7 5 binding is in some cases dispensable for biological response [Reviewed in Ibanez, 1994] . Nonetheless, it has been proposed that p75 regulates the biological response to neurotrophins by altering the affinity of neurotrophin binding to the Trk family receptors [Benedetti, et al., 1993; Reviewed in Chao, 1994] .
Data presented here suggests that differences in NRG-1, EGF, and BTC activities play a significant role in specifying the proliferation and differentiation of human tissues in vivo. These ligands may play their most significant role in the mammary epithelium and tissues of neuroectodermal origin. Not only has the expression of EGF family ligands been documented in these cell types, but these ligands can regulate the proliferation and/or differentiation of these cell types in cultured cell or animal model systems. Furthermore, mounting evidence suggests that, depending on the identity of the receptors, increased expression and/or signaling of ErbB family receptors may either stimulate or inhibit epithelial cell 
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Data adapted from Riese, et al., 1996a; Riese, et al., 1996b; Chang, et al., 1997; Riese and Stern, in press; Riese, et al., submitted. Page 33
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From Riese and Stern, unpublished data.
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